An anti-CSF1R monoclonal antibody for chronic graft-versus-host disease
Axatilimab
A specialist antibody infusion used for chronic graft-versus-host disease after a stem-cell transplant.
What is Axatilimab?
Axatilimab is a specialist medicine for chronic graft-versus-host disease, a condition that can develop after a stem-cell or bone-marrow transplant in which the donor's immune cells attack the recipient's own tissues. It is a monoclonal antibody that targets a signal (CSF1R) used by certain immune cells that drive the inflammation and scarring of this condition, helping to calm it. It is given as a drip into a vein under specialist care. Things to watch for include infusion reactions, infections, raised liver enzymes and a muscle blood marker called CK, and swelling around the eyes.
Education and reference only. This is a plain-language guide to Axatilimab — it deliberately contains no doses. Doses depend on the person, the brand and the reason for treatment, and belong with your prescriber. Always check the BNF, the product labelling (SmPC) and follow medical advice.
What it is
Axatilimab is a monoclonal antibody, a laboratory-made protein that targets a specific part of the immune system. It is used to treat chronic graft-versus-host disease, a complication that can follow a stem-cell or bone-marrow transplant where the transplanted donor immune cells attack the recipient's own tissues, causing inflammation and scarring in the skin, mouth, eyes, gut and other organs. Axatilimab is given as an infusion (drip) into a vein, usually after other treatments have been tried, and is prescribed and supervised by a specialist transplant team.
How it works
Chronic graft-versus-host disease is driven in part by certain immune cells called macrophages, which rely on a signal received through a receptor called CSF1R to survive and become active. Axatilimab blocks CSF1R, reducing the number and activity of these cells, which helps dampen the inflammation and scarring they cause in the affected organs. By targeting this particular pathway, it offers a way to calm the disease that is different from broad immune-suppressing medicines. It is given as a drip on a regular schedule set by the specialist team.
Company & origin
Originated / developed by: Specialist manufacturer.
A specialist infusion used in the UK for chronic graft-versus-host disease after a stem-cell or bone-marrow transplant, given by transplant teams.
Practical use
How to take Axatilimab
General, dose-free guidance — always follow your prescriber's and the leaflet's specific instructions.
- It is given as a drip into a vein by your specialist transplant team, on the schedule they set.
- Attend all your infusion and blood-test appointments, as regular monitoring is part of treatment.
- Report any signs of infection, such as fever or chills, promptly, as your immune system is affected.
- Tell the team if you notice swelling around the eyes or new muscle aches.
- Mention any reaction during or shortly after the drip, such as flushing, chills or breathlessness.
Weighing it up
Advantages & disadvantages of Axatilimab
Advantages
- Targets a specific immune pathway (CSF1R) that drives chronic graft-versus-host disease.
- Offers an option for people whose disease has not responded to earlier treatments.
- Works differently from broad immune-suppressing medicines, calming the inflammation and scarring.
Disadvantages
- Can increase the risk of infections by affecting the immune system.
- May cause infusion reactions, raised liver enzymes or muscle marker (CK), and swelling around the eyes.
- Given as a drip in hospital with regular monitoring, requiring specialist supervision.
Practical use
Good to know
Because axatilimab affects the immune system, infections are an important risk, so it is sensible to report fevers, chills or other signs of infection promptly to the transplant team. Infusion reactions can happen while the drip is running, so it is given where staff can watch for and treat them. The team also checks blood tests, as axatilimab can raise liver enzymes and a muscle marker called CK (creatine kinase), and swelling around the eyes (periorbital oedema) is a recognised effect. It is one part of managing chronic graft-versus-host disease, usually after other treatments, and is given alongside the rest of your transplant follow-up. Keeping all appointments and blood tests, and telling the team about any new symptoms, helps keep treatment safe.
Who should not take it / use with caution
- People who have had a serious allergic reaction to axatilimab should not receive it.
- It is used with caution in people with an active infection, which the team will assess first.
- It is used with care in pregnancy and breastfeeding, with the specialist weighing benefits and risks.
Monitoring
- Regular blood tests, including liver enzymes and the muscle marker CK.
- Watching for infusion reactions during and after the drip.
- Reviewing for signs of infection and swelling around the eyes over time.
Side effects
- Infusion reactions such as flushing, chills or breathlessness during or after the drip.
- Infections, because the immune system is affected.
- Raised liver enzymes or a raised muscle marker (CK) on blood tests, and swelling around the eyes.
Key interactions
- Other medicines that lower the immune system may add to the infection risk and need review.
- Live vaccines are generally avoided while the immune system is affected, so check before any vaccination.
- Tell your team about all your medicines, including those for your transplant follow-up.
Available as: A solution given as an infusion (drip) into a vein in hospital.
Answers
Axatilimab: frequently asked questions
What is axatilimab used for?
It is used to treat chronic graft-versus-host disease, a complication after a stem-cell or bone-marrow transplant where donor immune cells attack the recipient's own tissues.
How does it work?
It is a monoclonal antibody that blocks CSF1R, a signal used by certain immune cells (macrophages) that drive the inflammation and scarring of the condition.
How is it given?
It is given as a drip into a vein by your specialist transplant team, on a regular schedule, with monitoring during and after.
What should I watch out for?
Report signs of infection, any reaction during the drip, swelling around the eyes or new muscle aches; the team also checks liver enzymes and a muscle marker on blood tests.
Can I have vaccines while on it?
Live vaccines are generally avoided while the immune system is affected, so always check with your team before any vaccination.
Authoritative sources
- BNF
- NICE CKS
Building a medicines information resource?
We create evidence-led, dose-free drug and formulary references for teams.